KINDLIA Trademark

Trademark Overview


On Tuesday, July 16, 2019, a trademark application was filed for KINDLIA with the United States Patent and Trademark Office. The USPTO has given the KINDLIA trademark a serial number of 88517655. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 20, 2022. This trademark is owned by Amgen Inc.. The KINDLIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders; pharmaceutical preparations used for the treatment of renal and kidney disorders; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, metabolic diseases and disorders; pharmaceuticals for stimulating the growth of platelets and platelet precursor cells; erythropoiesis stimulating protein; pharmaceuticals for stimulating white blood cell production; pharmaceuticals for modulating the level of calcium in the bloodstream and for the treatment of hyperparathyroidism and hypercalcemia; pharmaceuticals for treating human immune diseases and conditions; pharmaceutical preparations for the tre...
kindlia

General Information


Serial Number88517655
Word MarkKINDLIA
Filing DateTuesday, July 16, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 20, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 24, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders; pharmaceutical preparations used for the treatment of renal and kidney disorders; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, metabolic diseases and disorders; pharmaceuticals for stimulating the growth of platelets and platelet precursor cells; erythropoiesis stimulating protein; pharmaceuticals for stimulating white blood cell production; pharmaceuticals for modulating the level of calcium in the bloodstream and for the treatment of hyperparathyroidism and hypercalcemia; pharmaceuticals for treating human immune diseases and conditions; pharmaceutical preparations for the treatment of bone disease; and pre-filled syringes containing pharmaceutical preparations for treatment of the aforementioned diseases and disorders and complications associated therewith

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 24, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Tuesday, June 21, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 20, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, November 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 2, 2021SOU EXTENSION 3 GRANTED
Tuesday, November 2, 2021SOU EXTENSION 3 FILED
Tuesday, November 2, 2021SOU TEAS EXTENSION RECEIVED
Thursday, May 6, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 6, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, May 6, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 6, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, May 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 4, 2021SOU EXTENSION 2 GRANTED
Tuesday, May 4, 2021SOU EXTENSION 2 FILED
Tuesday, May 4, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, November 3, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 30, 2020SOU EXTENSION 1 GRANTED
Friday, October 30, 2020SOU EXTENSION 1 FILED
Friday, October 30, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, May 19, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 24, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 24, 2020PUBLISHED FOR OPPOSITION
Wednesday, March 4, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 18, 2020ASSIGNED TO LIE
Monday, February 10, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, February 6, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 3, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 3, 2019NON-FINAL ACTION E-MAILED
Tuesday, September 3, 2019NON-FINAL ACTION WRITTEN
Monday, August 26, 2019ASSIGNED TO EXAMINER
Wednesday, July 24, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 19, 2019NEW APPLICATION ENTERED